Koers Pathfinder Cell Therapy, Inc. Other OTC
Aandelen
PFND
US70319A1060
Biotechnologie & Medisch Onderzoek
Omzet 2013 | 0,05 0,05 | Omzet 2014 | - | Marktkapitalisatie | 534K 494K |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -1 mln. -926K | Nettowinst (verlies) 2014 | -1 mln. -926K | EV/omzet 2013 | 246.023.185 x |
Nettoschuld 2013 | 3,94 mln. 3,65 mln. | Nettoschuld 2014 | 4,96 mln. 4,59 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-5,48
x | K/w-verhouding 2014 |
-0,38
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 02-09-11 |
John Benson
DFI | Director of Finance/CFO | 62 | 02-09-11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,85% | 57,87 mld. | |
+41,42% | 40,25 mld. | |
-5,25% | 39,94 mld. | |
-5,16% | 28,54 mld. | |
+12,79% | 26,4 mld. | |
-20,18% | 19,33 mld. | |
+30,88% | 12,4 mld. | |
+0,61% | 12,23 mld. | |
+25,06% | 12,2 mld. |